Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 6,433 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
DCR-PHXC, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 10:14 AM EDT
Terminated Phase 4 Interventional

Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D

NCT01312441
View directory record Official record
Conditions
Vitamin D Deficiency, Renal Failure Chronic Requiring Hemodialysis
Interventions
Ergocalciferol, Placebo
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Albany, New York • Clifton Park, New York • Saratoga Springs, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

NCT00440466
View directory record Official record
Conditions
Anemia, Renal Diseases
Interventions
epoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
66
States / cities
Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 10:14 AM EDT
Not listed Phase 2 Interventional

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

NCT00093522
View directory record Official record
Conditions
Kidney Cancer
Interventions
autologous tumor cell vaccine, keyhole limpet hemocyanin, therapeutic autologous dendritic cells, fludarabine phosphate, conventional surgery
Biological · Drug · Procedure
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Octreotide in Severe Polycystic Liver Disease

NCT00426153
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy

NCT00842023
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Nesiritide, Nitroglycerin
Drug
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Inglewood, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 20, 2026, 10:14 AM EDT
Recruiting Phase 2 Interventional

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

NCT07188896
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
Fianlimab, Ipilimumab, Nivolumab, Cemiplimab
Drug
Lead sponsor
Brian Rini
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chapel Hill, North Carolina • Hershey, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 20, 2026, 10:14 AM EDT
Recruiting Not applicable Interventional

Enhancing Physical Function in Older Adults With Chronic Kidney Disease

NCT06738394
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
High-Velocity Resistance Training, Attention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 10:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protective Immunity Project 02

NCT00833651
View directory record Official record
Conditions
Kidney Transplant, Immunology, Immunosuppression
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis

NCT00004495
View directory record Official record
Conditions
End Stage Renal Disease, Hyperhomocysteinemia
Interventions
cyanocobalamin, folic acid, pyridoxine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 89 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 20, 2026, 10:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Questionnaire Administration, Biospecimen Collection
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
40 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
747
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 502 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 4 Interventional

Osteopenia and Renal Osteodystrophy: Evaluation and Management

NCT00108394
View directory record Official record
Conditions
Osteopenia, Renal Osteodystrophy
Interventions
pamidronate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers

NCT00234156
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
oral fructose and high fat diet
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Study of Home-Embedded Palliative Care for Hemodialysis-Dependent End-Stage Renal Disease

NCT05471622
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Nudge for PHPC Referral
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 20, 2026, 10:14 AM EDT
Active, not recruiting Not applicable Interventional

Virtually Supervised Exercise for Kidney Transplant Candidates

NCT05355545
View directory record Official record
Conditions
Physical Disability
Interventions
Virtually supervised exercise, Health education
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

NCT00436657
View directory record Official record
Conditions
Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
Interventions
CHPP of Cisplatin, Abdominal Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

NCT01688973
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Tivantinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
214
States / cities
Tucson, Arizona • Anaheim, California • Baldwin Park, California + 154 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Uric Acid Lowering Trial in Youth Onset T2D

NCT03899883
View directory record Official record
Conditions
Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions
Pegloticase 8 MG/ML [Krystexxa]
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

NCT01200394
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
PF-00489791, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
63
States / cities
Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 20, 2026, 10:14 AM EDT
Terminated Not applicable Interventional Results available

Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease

NCT00638222
View directory record Official record
Conditions
Vascular Disease, Kidney Disease
Interventions
Carvedilol and Placebo
Other
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Toledo, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05940402
View directory record Official record
Conditions
Renal Impairment
Interventions
Emraclidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 20, 2026, 10:14 AM EDT
Not listed Not applicable Interventional

Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma

NCT04424472
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Ultrasonography
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

NCT01114672
View directory record Official record
Conditions
Pruritis
Interventions
50,000 Units Ergocalciferol, Placebo
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Bethpage, New York • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 20, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

NCT01711723
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 20, 2026, 10:14 AM EDT